News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW. 

This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research. 

The top stories: 

 

 

Wegovy pill could help patients lose 17% body weight  

The tablet version of Wegovy, approved in the UK by MHRA, is the first GLP-1 weight-loss pill licensed for weight management in the UK and is expected to become available from early July.  

Read more… 

 

 

Ulcerative colitis treatment shows best-in-class potential  

Biotechnology company Spyre Therapeutics has reported results from the Phase II SKYLINE trial evaluating SPY002, an extended half-life investigational antibody targeting TL1A. 

Read more… 

 

 

Therapy enables 89% survival rate in myeloma patients  

A combination treatment has demonstrated strong survival rates in patients with earlier-line relapsed or refractory multiple myeloma. 

Read more… 

 

 

A potentially practice-changing advance in bile duct cancer 

Results presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from the Phase III FIGHT-302 trial showed that Incyte’s pemigatinib (Pemazyre), significantly improved progression-free survival in the first-line setting in cholangiocarcinoma (bile duct cancer).  

Read more… 

 

 

Cancer Research UK to invest £17m in Manchester Institute  

Cancer Research UK is set to invest £17 million ($23 million) and create up to 100 new jobs in a boost to the charity’s Manchester Institute. 

Read more…